Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease

Current Rheumatology Reports

Volumn 13, Issue 3, 2011, Pages 192-198

  Quick, Adam ^a   Tandan, Rup ^b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Dermatomyositis; IBM; Inclusion body myositis; Inflammatory myopathy; Intravenous immunoglobulin; IVIG; Mechanism of action; Polymyositis

Indexed keywords

COMPLEMENT; IMMUNOGLOBULIN; INTERCELLULAR ADHESION MOLECULE 1; PLACEBO; PREDNISONE;

ADD ON THERAPY; ARTICLE; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GENE EXPRESSION; HUMAN; IMMUNE SYSTEM; INCLUSION BODY MYOSITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MUSCLE TISSUE; PATHOGENESIS; POLYMYOSITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 85027943802     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0171-0     Document Type: Article

References (50)

1. P Imbach S Barandun V d'Apuzzo, et al. 1981 High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood Lancet 1 1228 1231 6112565 10.1016/S0140-6736(81)92400-4 1:STN:280:DyaL3M7ps1Cjtw%3D%3D
2. JB Bussel RP Kimberly RD Inman, et al. 1983 Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura Blood 62 480 486 6191803 1:STN:280:DyaL3s3lslOqtQ%3D%3D (Pubitemid 13036102)
3. E Schuller A Govaerts 1983 First results of immunotherapy with immunoglobulin G in multiple sclerosis patients Eur Neurol 22 205 212 6861805 10.1159/000115560 1:STN:280:DyaL3s3jsVGntQ%3D%3D (Pubitemid 13099207)
4. P Gajdos H Outin D Elkharrat, et al. 1984 High-dose intravenous gammaglobulin for myasthenia gravis Lancet 1 406 407 6198570 10.1016/S0140-6736(84)90469-0 1:STN:280:DyaL2c7hs1Cntg%3D%3D (Pubitemid 14183305)
5. PD Donofrio A Berger TH Brannagan 3rd, et al. 2009 Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM Ad Hoc Committee Muscle Nerve 40 890 900 19768755 10.1002/mus.21433 1:CAS:528:DC%2BD1MXhsVGmsbvL This report from the American Academy of Neuromuscular and Electrodiagnostic Medicine Task Force provides a comprehensive, evidence-based consensus statement on the treatment of immune-mediated neuromuscular disorders with IVIG
6. HW Schroeder Jr L Cavacini 2010 Structure and function of Immunoglobulins J Allergy Clin Immunol 125 S41 S52 20176268 10.1016/j.jaci.2009.09.046
7. MD Kazatchkine SV Kaveri 2001 Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin N Engl J Med 345 747 755 11547745 10.1056/NEJMra993360 1:CAS:528:DC%2BD3MXmvFKjsLg%3D
8. DL Tankersley MS Preston JS Finlayson 1988 Immunoglobulin G dimer: an idiotype-anti-idiotype complex Mol Immunol 25 41 48 3343971 10.1016/0161- 5890(88)90088-0 1:CAS:528:DyaL1cXlsVSltQ%3D%3D (Pubitemid 18011285)
9. T Tha-In HJ Metselaar HW Tilanus, et al. 2007 Intravenous immunoglobulins suppress T-cell priming by modulating the bidirectional interaction between dendritic cells and natural killer cells Blood 110 3253 3262 17673603 10.1182/blood-2007-03-077057 1:CAS:528:DC%2BD2sXht1yqur3I (Pubitemid 350106318)
10. J Bayry S Lacroix-Desmazes C Carbonneil, et al. 2003 Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin Blood 101 758 765 12393386 10.1182/blood-2002-05-1447 1:CAS:528:DC%2BD3sXkvVaisw%3D%3D (Pubitemid 36077604)
11. R Liblau P Gajdos FA Bustarret, et al. 1991 Intravenous gamma-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies J Clin Immunol 11 128 131 1716263 10.1007/BF00918680 1:STN:280: DyaK3MzmsFymtg%3D%3D
12. T Vassilev C Gelin SV Kaveri, et al. 1993 Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg) Clin Exp Immunol 92 3 369 372 7685668 10.1111/j.1365-2249.1993.tb03407.x 1:CAS:528:DyaK3sXlvVygtb0%3D (Pubitemid 23183742)
13. ML Diegel BM Rankin JB Bolen, et al. 1994 Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel J Biol Chem 269 11409 11416 7512564 1:CAS:528:DyaK2cXivFKhu74%3D
14. E Bonnin MD Kazatchkine G Ruberti, et al. 1998 Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway J Immunol 161 3781 3790 9759905
15. M Basta MC Dalakas 1994 High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments J Clin Invest 94 1729 1735 7962520 10.1172/JCI117520 1:CAS:528:DyaK2MXhvFKhtLc%3D (Pubitemid 24348207)
16. J Bayary S Dasgupta N Misra, et al. 2006 Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms Int Immunopharmacol 6 528 534 16504915 10.1016/j.intimp.2005.11.013 1:CAS:528:DC%2BD28XhslyrsrY%3D
17. MC Dalakas I Illa JM Dambrosia, et al. 1993 A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis N Engl J Med 329 1993 2000 8247075 10.1056/NEJM199312303292704 1:STN:280:DyaK2c%2Fmslalsw%3D%3D (Pubitemid 24015043)
18. S Hurnaus W Mueller-Felber D Pongratz, et al. 2006 Serum levels of matrix metalloproteinases-2 and -9 and their tissue inhibitors in inflammatory neuromuscular disorders Eur Neurol 55 204 208 16772717 10.1159/000093870 1:CAS:528:DC%2BD28XnslWjurw%3D (Pubitemid 44174811)
19. E Carmeli M Moas AZ Reznick R Coleman 2004 Matrix metalloproteinases and skeletalmuscle: a brief review Muscle Nerve 29 191 197 14755482 10.1002/mus.10529 1:CAS:528:DC%2BD2cXhvVeqs7g%3D (Pubitemid 38166839)
20. VL Ott DC Fong JC Cambier, et al. 2001 Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy J Allergy Clin Immunol 108 S95 S98 11586273 10.1067/mai.2001.117822 1:CAS:528:DC%2BD3MXotFWlsLY%3D (Pubitemid 32978003)
21. A Samuelsson TL Towers JV Ravetch 2001 Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor Science 291 484 486 11161202 10.1126/science.291.5503.484 1:CAS:528:DC%2BD3MXlslensw%3D%3D (Pubitemid 32097072)
22. A Durandy SV Kaveri TW Kuijpers, et al. 2009 Intravenous immunoglobulins-understanding properties and mechanisms Clin Exp Immunol 58 Suppl 1 2 13 10.1111/j.1365-2249.2009.04022.x This review provides an excellent overview of some of the known mechanisms of action for IVIG and details how varied mechanisms may be relevant in different diseases
23. MC Dalakas R Hohlfeld 2003 Polymyositis and dermatomyositis Lancet 362 971 982 14511932 10.1016/S0140-6736(03)14368-1 1:CAS:528:DC%2BD3sXnsVWqu7g%3D (Pubitemid 37159295)
24. K Amemiya C Semino-Mora RP Granger, et al. 2000 Downregulation of TGF-beta1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin Clin Immunol 94 99 104 10637094 10.1006/clim.1999.4823 1:CAS:528:DC%2BD3cXhtFOktb4%3D (Pubitemid 30067874)
25. R Raju MC Dalakas 2005 Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes Brain 128 1887 1896 15857930 10.1093/brain/awh518 (Pubitemid 41373661)
26. SA Greenberg 2007 Proposed immunologic models of the inflammatory myopathies and potential therapeutic implications Neurology 69 2008 2019 17928577 10.1212/01.WNL.0000291619.17160.b8 (Pubitemid 350145093)
27. YC Choi MC Dalakas 2000 Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies Neurology 54 65 71 10636127 1:CAS:528:DC%2BD3cXoslShug%3D%3D (Pubitemid 30038739)
28. MC Dalakas 2010 Inflammatory muscle diseases: a critical review on pathogenesis and therapies Curr Opin Pharmacol 10 346 352 20409756 10.1016/j.coph.2010.03.001 1:CAS:528:DC%2BC3cXptVWmsrg%3D This reference describes some of the recent controversies in the proposed pathophysiology of the inflammatory myopathies and critically appraises the evidence behind the different theories
29. P Cherin S Pelletier A Teixeira, et al. 2002 Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients Arthritis Rheum 46 467 474 11840450 10.1002/art.10053 1:CAS:528:DC%2BD38XhvF2qsr0%3D (Pubitemid 34136585)
30. P Cherin S Herson B Wechsler, et al. 1991 Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients Am J Med 91 162 168 1714235 10.1016/0002-9343(91)90009-M 1:STN:280:DyaK3MzivVajtg%3D%3D
31. MC Dalakas B Sonies J Dambrosia, et al. 1997 Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study Neurology 48 712 716 9065553 1:STN:280:DyaK2s3hslyqsA%3D%3D (Pubitemid 27120112)
32. SA Soueidan MC Dalakas 1993 Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin Neurology 43 876 879 8492940 1:STN:280:DyaK3s3mtFKjtg%3D%3D (Pubitemid 23150554)
33. AA Amato RJ Barohn CE Jackson, et al. 1994 Inclusion body myositis: treatment with intravenous immunoglobulin Neurology 44 1516 1518 8058161 1:STN:280:DyaK2czjs1Sgsw%3D%3D (Pubitemid 24247450)
34. MC Dalakas B Koffman M Fujii, et al. 2001 A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM Neurology 56 323 327 11171896 1:CAS:528:DC%2BD3MXhsFGrsr0%3D (Pubitemid 32144142)
35. MC Dalakas 1994 Intravenous immune globulin for dermatomyositis N Eng J Med 330 1392 1393
36. MG Danieli G Malcangi C Palmieri, et al. 2002 Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis Ann Rheum Dis 61 37 41 11779756 10.1136/ard.61.1.37 1:CAS:528:DC%2BD38XntFamsg%3D%3D (Pubitemid 34074837)
37. Y Kuwano H Ihn N Yazawa, et al. 2006 Successful treatment of dermatomyositis with high-dose intravenous immunoglobulin Acta Derm Venereol 86 158 159 16648923 (Pubitemid 44020186)
38. FL Mastaglia BA Phillips PJ Zilko 1998 Immunoglobulin therapy in inflammatory myopathies J Neurol Neurosurg Psychiatry 63 107 110 10.1136/jnnp.65.1.107 (Pubitemid 28302366)
39. L Williams PY Chang E Park, et al. 2007 Successful treatment of dermatomyositis during pregnancy with intravenous immunoglobulin monotherapy Obstet Gynecol 109 2 Pt 2 561 563 17267895 10.1097/01.AOG.0000253244.45837.7c 1:CAS:528:DC%2BD2sXitVeht7c%3D (Pubitemid 46146861)
40. P Cherin JC Piette B Wechsler, et al. 1994 Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients J Rheumatol 21 1092 1097 7932419 1:STN:280:DyaK2M%2Fhsl2jsQ%3D%3D (Pubitemid 24182283)
41. A Sansome V Dubowitz 1995 Intravenous immunoglobulin in juvenile dermatomyositis-four year review of nine cases Arch Dis Child 72 25 28 7717731 10.1136/adc.72.1.25 1:STN:280:DyaK2M3jtlOrsA%3D%3D
42. MJ Tsai CC Lai SC Lin, et al. 1997 Intravenous immunoglobulin therapy in juvenile dermatomyositis Zhonghua Min Guo Xiao Erke Yi Xue Hui Za Zhi 38 111 115 1:CAS:528:DyaK1cXhtlSksrw%3D
43. SM Al-Mayouf RM Laxer R Schneider, et al. 2000 Intravenous immunoglobulin therapy for juvenile dermatomyositis-efficacy and safety J Rheumatol 27 2498 2503 11036850 1:CAS:528:DC%2BD3cXnsFCqsL8%3D
44. P Cherin O Chosidow S Herson 1995 Polymyositis and dermatomyositis Ann Dermatol Venereol 122 47 54
45. MC Dalakas 2004 Intravenous immunoglobulin in autoimmune neuromuscular diseases JAMA 291 2367 2375 15150209 10.1001/jama.291.19.2367 1:CAS:528:DC%2BD2cXkt1Sjsbo%3D (Pubitemid 38656304)
46. S Geneway A Saudan-Kister P-A Guerne 2001 Intravenous gammaglobulins in refractory polymyositis: lower dose for maintenance treatment is effective Ann Rheum Dis 60 635 636 10.1136/ard.60.6.635 (Pubitemid 32493993)
47. MC Walter H Lochmuller M Toepfer, et al. 2000 High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study J Neurol 247 22 28 10701893 10.1007/s004150050005 1:STN:280: DC%2BD3c7mtlyhug%3D%3D (Pubitemid 30162508)
48. EFNS Task Force on the Use of Intravenous Immunoglobulin in Treatment of Neurological Diseases 2008 EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases Eur J Neurol 15 893 908 10.1111/j.1468-1331.2008.02246.x This paper offers evidence-based recommendations from the European Federation of Neurological Societies Task Force for the use of IVIG in treatment of neurological diseases
49. D Pongratz 2006 Therapeutic options in autoimmune inflammatory myopathies (dermatomyositis, polymyositis, inclusion body myositis) J Neurol 253 Suppl 5 V64 V65 16998756 10.1007/s00415-006-5010-2 (Pubitemid 44441157)
50. Recher M, Sahrbacher U, Bremer J, et al. Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatol Int. 2010, Jan 1 (Epub ahead of print).